Sugi Predict

Sugi Predict / Targets / DUSP22

DUSP22

Dual specificity protein phosphatase 22 · Q9NRW4 · DUSP22 on Sugi Atlas →

1,580 patent compounds predicted against DUSP22, 1,259 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL8289157 SCHEMBL8289157 0.52 11/20
SCHEMBL6789390 SCHEMBL6789390 1.00 9/20
SCHEMBL9917038 SCHEMBL9917038 0.77 9/20
SCHEMBL10035996 SCHEMBL10035996 0.77 9/20
SCHEMBL11116026 SCHEMBL11116026 0.59 9/20
SCHEMBL9618992 SCHEMBL9618992 0.54 9/20
SCHEMBL1877094 SCHEMBL1877094 0.80 8/20
SCHEMBL1877096 SCHEMBL1877096 0.80 8/20
SCHEMBL1877097 SCHEMBL1877097 0.80 8/20
SCHEMBL9613308 SCHEMBL9613308 0.76 8/20
SCHEMBL10035971 SCHEMBL10035971 0.52 8/20
SCHEMBL8003652 SCHEMBL8003652 0.66 7/20
SCHEMBL2116513 SCHEMBL2116513 0.63 7/20
SCHEMBL9613352 SCHEMBL9613352 0.61 7/20
SCHEMBL2184682 SCHEMBL2184682 0.57 7/20
SCHEMBL2184686 SCHEMBL2184686 0.57 7/20
SCHEMBL10035969 SCHEMBL10035969 0.68 6/20
SCHEMBL1882106 SCHEMBL1882106 0.68 6/20
SCHEMBL1882107 SCHEMBL1882107 0.68 6/20
SCHEMBL1882111 SCHEMBL1882111 0.68 6/20

Clinical trials — most relevant to DUSP22 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia PHASE3COMPLETED
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC PHASE2COMPLETED
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer PHASE2COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Palliative Thoracic Radiotherapy Plus BKM120 PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) PHASE1COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients. nanCOMPLETED
Biomarkers in Samples From Patients With Chronic Lymphocytic Leukemia Treated on Clinical Trial ECOG-2997 nanCOMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Genetic Identification (ID) of Segmental Dysplastic Nevi nanWITHDRAWN
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing nanRECRUITING
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Genetics and Psychopathology in the 22q11 Deletion Syndrome nanUNKNOWN
Molecular Mechanisms Underlying Prostate Cancer Disparities nanCOMPLETED
Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer nanUNKNOWN
Immune Signature of Palmoplantar Pustulosis nanCOMPLETED
RASopathy Biorepository nanRECRUITING
Clinically Actionable Tumor-Associated Antigens in Prostate Cancer nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a DUSP22 binder may also engage these)

ProteinNameSimilarity
Q99N11 — 1.000 Q99N11 →
Q6GQJ8 — 0.997 Q6GQJ8 →
Q566R7 — 0.995 Q566R7 →
P0C599 — 0.992 P0C599 →
Q1LWL2 — 0.991 Q1LWL2 →
Q5XHB2 — 0.991 Q5XHB2 →
P0C5A0 — 0.990 P0C5A0 →
P0C5A1 — 0.988 P0C5A1 →
P0C593 — 0.987 P0C593 →
Q8R4V2 — 0.986 Q8R4V2 →
Q4KL92 — 0.985 Q4KL92 →
Q4RQD3 — 0.985 Q4RQD3 →
P0C598 — 0.985 P0C598 →
P0C591 — 0.985 P0C591 →
Q9M8K7 — 0.984 Q9M8K7 →
P0C5A2 — 0.984 P0C5A2 →
A4IHU7 — 0.984 A4IHU7 →
B4F7B7 — 0.983 B4F7B7 →
Q8BK84 — 0.983 Q8BK84 →
Q9ZR37 — 0.983 Q9ZR37 →
Q68J44 — 0.983 Q68J44 →
Q8WTR2 — 0.982 Q8WTR2 →
P0C596 — 0.982 P0C596 →
P0C597 — 0.981 P0C597 →
Q8K4T5 — 0.981 Q8K4T5 →
Q9D7X3 — 0.979 Q9D7X3 →
Q9VVW5 — 0.978 Q9VVW5 →
Q641Z2 — 0.978 Q641Z2 →
P0C595 — 0.978 P0C595 →
Q9JLY7 — 0.978 Q9JLY7 →